Nano-rheological biomarkers for early and improved follow-up of pathologies associated to RBC deformability alteration

Patent metadata

Field	Value
Publication number	US-12596125-B2
Application number	US-202017618731-A
Country	US
Kind code	B2
Filing date	Jun 15, 2020
Priority date	Jun 14, 2019
Publication date	Apr 7, 2026
Grant date	Apr 7, 2026

Abstract

The present invention is directed to a method to detect in a blood sample whether the red blood cells (RBCs) contained in said blood sample present or not an alteration of their deformability by using molecular rotor (MR) able to penetrate RBCs cell membrane. The invention also relates to diagnostic methods of RBC related pathologies associated to the modification of the distribution of the viscosity, rigidity or deformability of RBCs by detection and measurement of the RBCs fluorescence intensity image intensity implementing optical methods. Finally, the present invention is directed to the use of MRs for testing the deformability of red blood cells (RBCs) in a blood sample and kit comprising MR and red blood cells (RBCs) control.

First claim

The invention claimed is:

1 . A method to detect in a test blood sample whether the red blood cells (RBCs) contained in the test blood sample present an alteration of their deformability, said method comprising the steps of:
a) mixing the test blood sample containing RBCs with a molecular rotor (MR) able to penetrate RBCs through their cell membranes to form a mixed test blood sample; a′) mixing a control blood sample known for exhibiting non alteration of RBC's deformability with a molecular rotor (MR) able to penetrate RBCs through their cell membranes to form a mixed control blood sample; a″) emitting an excitation light at 1) the mixed test blood sample to generate a test fluorescence signal and 2) the mixed control blood sample to generate a control fluorescence signal; b) quantifying a level of the test fluorescence signal emitted by the molecular rotor in the mixed test blood sample and a level of the control fluorescence signal emitted by the molecular rotor in the mixed control blood sample and/or analysing a distribution of fluorescence level in RBCs among cells in the mixed test blood sample and in the mixed control blood sample; and c) comparing the quantified test fluorescence signal and the quantified control fluorescence signal and/or the distribution of fluorescence level in RBCs obtained in step b) for the mixed test blood sample with the distribution of fluorescence level in RBCs obtained for the mixed control blood sample, wherein an increase in the test fluorescence signal and/or a modification of the distribution of fluorescence level in RBCs for the mixed test blood sample compared to the control fluorescence signal and/or the distribution of fluorescence level in RBCs of the mixed control blood sample defines an alteration of the RBCs deformability present in the test blood sample, and wherein said molecular rotor (MR) is trans-4-[4-(Dimethylamino) styril]-1-methylpyridinium (tDASMP).

2 . An in vitro method to identify whether a patient presents or to identify whether a patient is at risk to develop an RBC related pathology, said method comprising the steps of:
A) from a test blood sample containing RBCs obtained from the patient, detecting whether the RBCs present an alteration of their deformability by the method according to claim 1 ; and B) analysing detection results obtained in step A) for the test blood sample to determine whether the patient has an alteration of RBCs deformability, meaning said patient:
has an RBC related pathology, or
is at risk of developing an RBC related pathology,
wherein said RBC related pathology is selected from the group consisting of drepanocytosis, atherosclerosis, diabetes, malaria and Alzheimer's disease.

3 . The method according to claim 2 , wherein said RBC related pathology is drepanocytosis.

4 . The method according to claim 1 , wherein:
in step a) of the method of claim 1 , the test blood sample is diluted in a solution of molecular rotor (MR); in step a′) of the method of claim 1 , the control blood sample is diluted in a solution of molecular rotor (MR).

5 . A method for diagnosing a RBC related pathology in a blood sample from a subject, wherein said RBC related pathology is selected from the group consisting of drepanocytosis, atherosclerosis, diabetes, malaria and Alzheimer's disease, the method comprising:
i) mixing a blood sample containing RBCs from the subject with molecular rotor (MR), which generates a fluorescence signal; ii) emitting an excitation light at the mixture of the blood sample and molecular rotor (MR) to generate a fluorescence signal; and iii) determining by an optical method the following rheological properties of the RBCs: (a) distribution of rigidity; and/or (b) viscosity; and/or (c) deformability of the RBCs, by measuring a fluorescence intensity of an image of the blood sample, wherein said molecular rotor (MR) is the trans-4-[4-(Dimethylamino) styril]-1-methylpyridinium (tDASMP).

6 . The method according to claim 5 , wherein the optical method comprises utilizing a microscope coupled to a camera to image the blood sample.

7 . The method according to claim 5 , wherein said RBC related pathology is drepanocytosis.

8 . The method according to claim 5 , wherein:
in step i) the blood sample is diluted in a solution of molecular rotor (MR); and in step ii), a distribution of the RBCs fluorescence level is analysed and compared to a control sample.

9 . A kit to identify whether a patient presents or is at risk to develop a RBC related pathology, wherein said RBC related pathology is selected from the group consisting of drepanocytosis, atherosclerosis, diabetes, malaria and Alzheimer's disease, said kit comprising trans-4-[4-(Dimethylamino)styril]-1-methylpyridinium (tDASMP) and red blood cells (RBCs) control exhibiting non alteration of their deformability and/or exhibiting alteration of their deformability characteristic of said RBC related pathology.

10 . The kit according to claim 9 , wherein said RBC related pathology is drepanocytosis.

Assignees

• Alcediag
• Centre National De La Recherche Scient Cnrs
• Univ Paris Cite

Inventors

• Abou Bérengère
• Molina Franck
• Podgorski Thomas

Classifications

• G01N2015/012

  Red blood cells · CPC title

• G01N2800/22

  Haematology · CPC title

• G01N33/582

  with fluorescent label · CPC title

• G01N15/1434

  Optical arrangements · CPC title

• G01N2203/0089

  Biorheological properties · CPC title